Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26494241 | 0.93 | HRH3 (0.41) | HRH3SIGMAR1HSD11B1DRD2DRD3 | |
| SCHEMBL26295685 | 0.90 | HRH3 (0.43) | HRH3SIGMAR1HSD11B1DRD2DRD3 | |
| SCHEMBL26494238 | 0.90 | HPGD (0.44) | SIGMAR1HSD11B1DRD2DRD3TP53 | |
| SCHEMBL26295687 | 0.90 | HRH3 (0.50) | HRH3SIGMAR1HSD11B1DRD2DRD3 | |
| SCHEMBL26494239 | 0.88 | HRH3 (0.45) | HRH3SIGMAR1HSD11B1KCNH2CYP2D6 | |
| SCHEMBL26494244 | 0.86 | HPGD (0.46) | HRH3SIGMAR1HSD11B1KCNH2CYP2D6 | |
| SCHEMBL26263767 | 0.86 | HRH3 (0.50) | HRH3SIGMAR1HSD11B1DRD2DRD3 | |
| SCHEMBL26295683 | 0.84 | HRH3 (0.50) | HRH3SIGMAR1HSD11B1KCNH2CYP2D6 | |
| SCHEMBL26295692 | 0.83 | HRH3 (0.41) | HRH3SIGMAR1HSD11B1DRD2DRD3 | |
| SCHEMBL26494227 | 0.83 | HRH3 (0.45) | HRH3SIGMAR1HSD11B1KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | HRH3 3222/4885SIGMAR1 3987/4885HSD11B1 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.